Department of Medicine, National University Health System, Singapore General Hospital, Singapore.
J Formos Med Assoc. 2010 Sep;109(9):624-31. doi: 10.1016/S0929-6646(10)60102-7.
Febrile neutropenia remains a major cause of morbidity and mortality in patients receiving chemotherapy. Major prophylactic strategies include granulocyte colony-stimulating factor and antibiotics, the most widely used of which are fluoroquinolones. While fluoroquinolone prophylaxis has been shown to be effective in areas where fluoroquinolone resistance is low, this same efficacy has not been proven in areas where resistance is high, such as in Asia. Given the increase in antimicrobial resistance with the use of prophylaxis, the risks and benefits of this strategy need to be carefully considered. This review presents the evidence for and against fluoroquinolone prophylaxis in areas of high fluoroquinolone resistance.
发热性中性粒细胞减少症仍是接受化疗的患者发病和死亡的主要原因。主要的预防策略包括粒细胞集落刺激因子和抗生素，其中最广泛使用的是氟喹诺酮类药物。虽然氟喹诺酮类药物预防已被证明在氟喹诺酮类药物耐药率低的地区有效，但在耐药率高的地区（如亚洲），这种效果尚未得到证实。鉴于预防性使用导致抗菌药物耐药性增加，需要仔细考虑这种策略的风险和获益。本综述介绍了氟喹诺酮类药物预防在氟喹诺酮类药物耐药率高的地区的证据。
